Omega-3 Fatty Acids (fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease
Principal Investigator: Dr Ashley Irish
Clinical Research Associate: Peta-Anne Paul-Brent (AKTN)
Population: Stage 3/4 CKD patients undergoing or planning to undergo Haemodialysis with planned de novo AVF
Final recruitment number: 567 (target of 650)
Intervention: Aspirin (100mg) and/or Omega-3 (4,000mg) fatty acids versus placebo, daily for 12 weeks
Primary outcome: AVF Access Failure rate over 12 months
Results: The FAVOURED study is unable to recommend the use of fish oil or aspirin for the prevention of AVF failure. Additional studies and strategies to reduce the current unacceptably high AVF failure rate are urgently required. The results of the study have been presented as the ASN Kidney Week in November 2015 and the final results paper has been submitted to JAMA Internal Medicine (2016).